MFA Wealth Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-833
Closed -$210K – 94
2026
Q2
$210K Buy
+833
New +$179K 0.04% 96
2025
Q2
– Sell
-995
Closed -$208K – 89
2025
Q1
$208K Buy
+995
New +$193K 0.05% 87
2024
Q4
– Sell
-880
Closed -$174K – 78
2024
Q3
$174K Sell
880
-150
-15% -$28K 0.04% 102
2024
Q2
$177K Buy
+1,030
New +$171K 0.04% 106
2020
Q3
– Sell
-469
Closed -$46K – 40
2020
Q2
$46K Buy
+469
New +$41.3K 0.03% 76
2018
Q3
– Sell
-11,592
Closed -$1.1M – 53
2018
Q2
$1.1M Buy
11,592
+39
+0.3% +$3.81K 0.72% 27
2018
Q1
$1.16M Buy
11,553
+66
+0.6% +$7.25K 0.88% 23
2017
Q4
$1.34M Buy
+11,487
New +$1.08M 0.91% 24

Other funds holding ABBV

MFA Wealth Advisors's ABBV Position: Q3 2026 in Review

MFA Wealth Advisors sold out of AbbVie (ABBV) in Q3 2026, closing a stake of 833 shares — an estimated $210K sold.

MFA Wealth Advisors first reported a position in ABBV in Q4 2017 and held it in 8 quarters. The position peaked at $1.34M in Q4 2017. 2,874 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • MFA Wealth Advisors reported no remaining AbbVie position as of Q3 2026 after selling out during the quarter.
  • MFA Wealth Advisors sold 833 AbbVie shares in Q3 2026, an estimated $210K.
  • MFA Wealth Advisors first reported a position in AbbVie in Q4 2017 and held it in 8 quarters.
  • MFA Wealth Advisors's AbbVie position peaked at $1.34M in Q4 2017.
  • 2,874 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on MFA Wealth Advisors's 13F filing for Q3 2026, filed 7 Oct 2026.